Clearside Biomedical Inc (FRA:CLM)
€ 0.885 0.065 (7.93%) Market Cap: 69.14 Mil Enterprise Value: 47.25 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 67/100

Clearside Biomedical Inc at UBS Global Healthcare Conference Transcript

May 22, 2019 / 03:00PM GMT
Unidentified Analyst

(technical difficulty)

To the UBS Healthcare Conference. My name is [Andrew Dorskind]. I'll be your host for this session. Now it's my pleasure to introduce Brion Raymond, the Chief Commercial Officer, from Clearside Biomedical. And just note that immediately following the presentation, there will be a breakout session in the [Juilliard] Room.

Brion S. Raymond
Clearside Biomedical, Inc. - Chief Commercial Officer

Thank you, Andrew. Thank you, and good morning. Clearside Biomedical is dedicated to treating vision-threatening diseases in the back of eye through our proprietary technology that allows us to access the suprachoroidal space.

The combination of the suprachoroidal space, our proprietary microinjector and both novel and existing therapies allows us to bring new therapies and new clinical profiles to both existing and new drugs. And our lead product, XIPERE, is currently sitting in the FDA under review with an October PDUFA date or a PDUFA date of October 2019. The suprachoroidal injection platform really is a

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot